Tag Archives: New York Times

Has Delta Peaked?

This is a fascinating analysis of COVID’s two-month cycle, with the Delta variant following a similar pattern to the first outbreaks. (Apologies for formatting wonkiness — cutting and pasting NYT articles doesn’t always work well.)


A testing site in Auburndale, Fla., last month.Octavio Jones for The New York Times
Almost like clockwork

By David Leonhardt and Ashley Wu for The New York Times
Has the Delta-fueled Covid-19 surge in the U.S. finally peaked?
The number of new daily U.S. cases has risen less over the past week than at any point since June, as you can see in this chart:
The New York Times
There is obviously no guarantee that the trend will continue. But there is one big reason to think that it may and that caseloads may even soon decline.
Since the pandemic began, Covid has often followed a regular — if mysterious — cycle. In one country after another, the number of new cases has often surged for roughly two months before starting to fall. The Delta variant, despite its intense contagiousness, has followed this pattern.
After Delta took hold last winter in India, caseloads there rose sharply for slightly more than two months before plummeting at a nearly identical rate. In Britain, caseloads rose for almost exactly two months before peaking in July. In Indonesia, Thailand, France, Spain and several other countries, the Delta surge also lasted somewhere between 1.5 and 2.5 months.
* Between February and July 2021, depending on the country.The New York Times
And in the U.S. states where Delta first caused caseloads to rise, the cycle already appears to be on its downside. Case numbers in Arkansas, Florida, Louisiana, Mississippi and Missouri peaked in early or mid-August and have since been falling:
The New York Times
Two possible stories
We have asked experts about these two-month cycles, and they acknowledged that they could not explain it. “We still are really in the cave ages in terms of understanding how viruses emerge, how they spread, how they start and stop, why they do what they do,” Michael Osterholm, an epidemiologist at the University of Minnesota, said.
But two broad categories of explanation seem plausible, the experts say.
One involves the virus itself. Rather than spreading until it has reached every last person, perhaps it spreads in waves that happen to follow a similar timeline. How so? Some people may be especially susceptible to a variant like Delta, and once many of them have been exposed to it, the virus starts to recede — until a new variant causes the cycle to begin again (or until a population approaches herd immunity).
The second plausible explanation involves human behavior. People don’t circulate randomly through the world. They live in social clusters, Jennifer Nuzzo, a Johns Hopkins epidemiologist, points out. Perhaps the virus needs about two months to circulate through a typically sized cluster, infecting the most susceptible — and a new wave starts when people break out of their clusters, such as during a holiday. Alternately, people may follow cycles of taking more and then fewer Covid precautions, depending on their level of concern.
Whatever the reasons, the two-month cycle predated Delta. It has repeated itself several times in the U.S., including both last year and early this year, with the Alpha variant, which was centered in the upper Midwest:
What now?
The New York Times
In a few countries, vaccination rates have apparently risen high enough to break Covid’s usual two-month cycle: The virus evidently cannot find enough new people to infect. In both Malta and Singapore, this summer’s surge lasted only about two weeks before receding.
We want to emphasize that cases are not guaranteed to decline in coming weeks. There have been plenty of exceptions to the two-month cycle around the world. In Brazil, caseloads have followed no evident pattern. In Britain, cases did decline about two months after the Delta peak — but only for a couple of weeks. Since early August, cases there have been rising again, with the end of behavior restrictions likely playing a role. (If you haven’t yet read this Times dispatch about Britain’s willingness to accept rising caseloads, we recommend it.)
In the U.S., the start of the school year could similarly spark outbreaks this month. The country will need to wait a few more weeks to know. In the meantime, one strategy continues to be more effective than any other in beating back the pandemic: “Vaccine, vaccine, vaccine,” as Osterholm says. Or as Nuzzo puts it, “Our top goal has to be first shots in arms.”
The vaccine is so powerful because it keeps deaths and hospitalizations rare even during surges in caseloads. In Britain, the recent death count has been less than one-tenth what it was in January.

More Good News on Vaccines

Happy Hump Day! This info is very encouraging. Maybe we’re close to turning the corner on this vicious pandemic. How sad it didn’t happen much, much earlier. And if Congress defangs that crazy Marjorie Taylor Greene, it will be an all-around excellent week. Cheers!

[From New York Times]
“For once, we have some good news to talk about: the prospect of another vaccine coming online in the U.S., and a long-awaited indication that at least one vaccine reduces transmission, not just the severity of Covid-19.

Let’s start with the remarkable turnaround of the experimental vaccine from Novavax, a Maryland-based company that has never before brought a vaccine to market.

Last fall, Novavax postponed U.S. clinical trials because of manufacturing delays, jeopardizing the company’s $1.6 billion federal contract and leaving some to wonder whether they should write off the company’s shot entirely. In December, Novavax watched from the sidelines as the Pfizer-BioNTech and Moderna vaccines were approved.

But things have changed. Novavax announced last week that its vaccine produced robust protection in a large British trial and that it worked — although far less well — in a smaller study in South Africa. The company has also been able to quickly recruit volunteers for its U.S. trials because the two authorized vaccines have been difficult to get, and many see the Novavax trial as their best chance to get vaccinated.

So the company now stands a chance of having trial results this spring, with possible government authorization as early as April. If everything goes well, and that is a big if, Novavax could deliver enough additional doses to vaccinate 55 million Americans by the end of June. That would be on top of the 400 million doses that Moderna and Pfizer are contracted to supply the U.S. by the middle of the year — enough for 200 million people.

It gets better: Novavax has been laying the international groundwork for the eventual production of two billion doses per year — and its vaccine, unlike Moderna and Pfizer’s, can be stored and shipped at normal refrigeration temperatures.

As for protection against transmission, AstraZeneca recently released a report that offered an answer to one of the pandemic’s big questions: Will vaccines prevent people from giving the virus to others?

Researchers from the University of Oxford and AstraZeneca have found that not only did their vaccine protect people from serious illness and death but also had the potential to reduce transmission. Swabs taken from trial participants showed a 67 percent reduction in virus being detected among those vaccinated, though scientists warned that the data was preliminary and that masking remained necessary for all.

The AstraZeneca-Oxford vaccine is in U.S. trials, and the company has a deal to supply 300 million doses, enough for another 150 million people.”

Good News Monday: Statins, stat!

For us older folks with cholesterol concerns — mine’s hereditary; thanks, Dad — today’s NY Times article had some heartening info.

For Older People, Reassuring News in the Statin Debate

There is accumulating evidence that the benefits of statins far outweigh possible risks, and nearly all statins on the market are now available as inexpensive generics.

Credit…Gracia Lam
Jane E. Brody

By Jane E. Brody

  • Sept. 21, 2020, 5:00 a.m. ET

Cholesterol-lowering statin drugs, already one of the most popular medications worldwide, may become even more widely used as evidence grows of their safety and value to the elderly and their potential benefits beyond the heart and blood vessels.

Among the latest are reports of the ability of several leading statins to reduce deaths from common cancers and blunt the decline of memory with age. Perhaps such reports will persuade a reluctant 65-year-old friend who has diabetes, and others like him, that taking the statin his doctor strongly advised is a smart choice.

In addition to accumulating evidence that the benefits of statins far outweigh possible risks for the vast majority of people for whom they are now recommended, nearly all statins on the market are now available as inexpensive generics.

Full disclosure: I have a strong family history of heart disease and have been taking a statin — atorvastatin, originally marketed as Lipitor — for many years after dietary changes failed to control a steadily rising blood level of artery-damaging LDL-cholesterol. My prescription is now fully covered by my Medicare Part D insurance with no co-pay.

But cost of a medication is not the only consideration for a drug that can be lifesaving for many people. The primary indication for taking a statin is to reduce the risk of a heart attack or stroke by lowering serum LDL-cholesterol and, in some cases, also triglycerides, both of which can damage coronary arteries when levels rise above normal.

Statins offer further cardiovascular protection by stabilizing the fatty deposits in arteries called plaque that can break loose, block a major artery and cause a heart attack or stroke.

Current guidelines typically recommend statin therapy for:

  • People with a history of heart disease, stroke or peripheral artery disease or risk factors that give them a 10 percent or greater chance of a heart attack within 10 years;
  • People over 40 with diabetes and an LDL-cholesterol level above 70 milligrams per deciliter;
  • People over 21 with an LDL-cholesterol level of 190 or higher (despite dietary changes to minimize saturated fats and achieve a normal body weight).

Currently, more than 60 percent of older people in the United States who, like me, have high cholesterol take a statin to help prevent a heart attack or stroke.

Still, there’s been a long-simmering debate as to whether statins are advisable for people over 75, even though the risk of suffering life-threatening cardiovascular disease rises precipitously with age. Concerns have been raised about side effects associated with statins, potential adverse effects of the drugs on other ailments common in the elderly and possible harmful interactions with the many other medications they often take.

Writing in the Harvard Health Blog last October, Dr. Dara K. Lee Lewis noted, “The paradox that we face is that as our patients age, they are at increased risk for heart attacks and strokes, and yet they also become more sensitive to medication side effects, so it is a tricky balance.”

Statins can sometimes cause blood sugar abnormalities, resulting in a diagnosis of pre-diabetes or diabetes, and possible toxic effects on the liver that necessitate periodic blood tests for liver enzymes. A very small percentage of people prescribed a statin develop debilitating muscle pain. An elderly friend developed statin-induced nightmares. There have also been reports suggesting statin-associated memory problems and cognitive decline, already a common concern as people age.

But likely the biggest deterrent was the existence of meager evidence for the role statins might play for older people at risk of cardiovascular disease. As is true in most drug trials on new medications, relatively few people over 75 were included in early studies that assessed the benefits and risks of statins.

The latest reports, however, are highly reassuring. One followed more than 120,000 French men and women ages 75 to 79 who had been taking statins for up to four years. Among the 10 percent who stopped taking the drug, the risk of being admitted to a hospital for a cardiovascular event was 25 to 30 percent greater than for those who continued taking a statin.

Another study in Israel, published last year in the Journal of the American Geriatrics Society, involved nearly 20,000 older adults followed for 10 years. Among those who stayed on statin therapy, the chance of dying from any cause was 34 percent lower than among those who failed to adhere to a prescribed statin. The benefits were not reduced for those older than 75 and applied to women and men alike.

This year a study published in JAMA by a team headed by Dr. Ariela R. Orkaby of the VA Boston Healthcare System found that among 326,981 United States veterans whose average age was 81, the initiation of statin use was associated with 25 percent fewer deaths over all and 20 percent fewer cardiovascular deaths during a follow-up of nearly seven years.

However, none of these studies represent “gold standard” research. The results of two such studies, the Staree trial and the Preventable trial, both randomized controlled clinical trials of statin therapy to prevent cardiovascular events in the elderly, have not yet been published. Both will also assess effects on cognition.

Meanwhile, a report last year from Australia published in the Journal of the American College of Cardiology found no difference over a six-year period in the rate of decline in memory or cognitive status between statin users and those who had never taken the drugs. In fact, among those who started a statin during the study, the rate of memory decline was blunted. Another observational study by a Swedish team published in Nature found beneficial effects on reaction time and fluid intelligence among statin takers over 65.

Finally, there are several reports that a major class of statins called lipophilic (including atorvastatin, simvastatin, lovastatin and fluvastatin) may have anticancer effects. One study of nearly 2,000 survivors of early-stage breast cancer found a decreased five-year recurrence rate in women who started a statin within three years of diagnosis.

In a report presented in June to a virtual meeting of the American Association for Cancer Research, Dr. Kala Visvanathan of Johns Hopkins Medicine in Baltimore described a 40 percent reduction in deaths from ovarian cancer among more than 10,000 patients who had used statins either before or after their diagnosis. The patients who benefited in this observational study had the most common and aggressive form of ovarian cancer.

Dr. Visvanathan explained that statins inhibit an enzyme in a chemical pathway involved in the growth and proliferation of tumors. At a press briefing, Dr. Antoni Ribas, president of the association, said that if the finding is confirmed in a randomized clinical trial, “this would be a great outcome.”

Good News Monday: An Expert Speaks

With so much misinformation out there, it’s useful to listen to people who actually know what they’re talking about. (Hint: Not politicians.)  While the below article is sobering, it does explain how we can avoid catching the virus.  And that’s good news.

[Reprinted from today’s New York Times]

Updated: 7 hours ago

The Risks – Know Them – Avoid Them

It seems many people are breathing some relief, and I’m not sure why. An epidemic curve has a relatively predictable upslope and once the peak is reached, the back slope can also be predicted. We have robust data from the outbreaks in China and Italy, that shows the backside of the mortality curve declines slowly, with deaths persisting for months. Assuming we have just crested in deaths at 70k, it is possible that we lose another 70,000 people over the next 6 weeks as we come off that peak. That’s what’s going to happen with a lockdown.

As states reopen, and we give the virus more fuel, all bets are off. I understand the reasons for reopening the economy, but I’ve said before, if you don’t solve the biology, the economy won’t recover.

There are very few states that have demonstrated a sustained decline in numbers of new infections. Indeed, the majority are still increasing and reopening. As a simple example of the USA trend, when you take out the data from New York and just look at the rest of the USA, daily case numbers are increasing. Bottom line: the only reason the total USA new case numbers look flat right now is because the New York City epidemic was so large and now it is being contained.

So throughout most of the country we are going to add fuel to the viral fire by reopening. It’s going to happen if I like it or not, so my goal here is to try to guide you away from situations of high risk.

Where are people getting sick?

We know most people get infected in their own home. A household member contracts the virus in the community and brings it into the house where sustained contact between household members leads to infection.

But where are people contracting the infection in the community? I regularly hear people worrying about grocery stores, bike rides, inconsiderate runners who are not wearing masks…. are these places of concern? Well, not really. Let me explain.

In order to get infected you need to get exposed to an infectious dose of the virus; based on infectious dose studies with MERS and SARS, some estimate that as few as 1000 SARS-CoV2 viral particles are needed for an infection to take hold. Please note, this still needs to be determined experimentally, but we can use that number to demonstrate how infection can occur. Infection could occur, through 1000 viral particles you receive in one breath or from one eye-rub, or 100 viral particles inhaled with each breath over 10 breaths, or 10 viral particles with 100 breaths. Each of these situations can lead to an infection.

How much Virus is released into the environment?

A Bathroom: Bathrooms have a lot of high touch surfaces, door handles, faucets, stall doors. So fomite transfer risk in this environment can be high. We still do not know whether a person releases infectious material in feces or just fragmented virus, but we do know that toilet flushing does aerosolize many droplets. Treat public bathrooms with extra caution (surface and air), until we know more about the risk.

A Cough: A single cough releases about 3,000 droplets and droplets travels at 50 miles per hour. Most droplets are large, and fall quickly (gravity), but many do stay in the air and can travel across a room in a few seconds.

A Sneeze: A single sneeze releases about 30,000 droplets, with droplets traveling at up to 200 miles per hour. Most droplets are small and travel great distances (easily across a room).

If a person is infected, the droplets in a single cough or sneeze may contain as many as 200,000,000 (two hundred million) virus particles which can all be dispersed into the environment around them.

A breath: A single breath releases 50 – 5000 droplets. Most of these droplets are low velocity and fall to the ground quickly. There are even fewer droplets released through nose-breathing. Importantly, due to the lack of exhalation force with a breath, viral particles from the lower respiratory areas are not expelled.

Unlike sneezing and coughing which release huge amounts of viral material, the respiratory droplets released from breathing only contain low levels of virus. We don’t have a number for SARS-CoV2 yet, but we can use influenza as a guide. We know that a person infected with influenza releases about 3 – 20 virus RNA copies per minute of breathing.

Remember the formulae: Successful Infection = Exposure to Virus x Time

If a person coughs or sneezes, those 200,000,000 viral particles go everywhere. Some virus hangs in the air, some falls into surfaces, most falls to the ground. So if you are face-to-face with a person, having a conversation, and that person sneezes or coughs straight at you, it’s pretty easy to see how it is possible to inhale 1,000 virus particles and become infected.

But even if that cough or sneeze was not directed at you, some infected droplets–the smallest of small–can hang in the air for a few minutes, filling every corner of a modest sized room with infectious viral particles. All you have to do is enter that room within a few minutes of the cough/sneeze and take a few breaths and you have potentially received enough virus to establish an infection.

But with general breathing, 20 copies per minute into the environment, even if every virus ended up in your lungs, you would need 1000 copies divided by 20 copies per minute = 50 minutes.

Speaking increases the release of respiratory droplets about 10 fold; ~200 copies of virus per minute. Again, assuming every virus is inhaled, it would take ~5 minutes of speaking face-to-face to receive the required dose.

The exposure to virus x time formulae is the basis of contact tracing. Anyone you spend greater than 10 minutes with in a face-to-face situation is potentially infected. Anyone who shares a space with you (say an office) for an extended period is potentially infected. This is also why it is critical for people who are symptomatic to stay home. Your sneezes and your coughs expel so much virus that you can infect a whole room of people.

What is the role of asymptomatic people in spreading the virus?

Symptomatic people are not the only way the virus is shed. We know that at least 44% of all infections–and the majority of community-acquired transmissions–occur from people without any symptoms (asymptomatic or pre-symptomatic people). You can be shedding the virus into the environment for up to 5 days before symptoms begin.

Infectious people come in all ages, and they all shed different amounts of virus. The figure below shows that no matter your age (x-axis), you can have a little bit of virus or a lot of virus (y-axis). (ref)

The amount of virus released from an infected person changes over the course of infection and it is also different from person-to-person. Viral load generally builds up to the point where the person becomes symptomatic. So just prior to symptoms showing, you are releasing the most virus into the environment. Interestingly, the data shows that just 20% of infected people are responsible for 99% of viral load that could potentially be released into the environment (ref)

So now let’s get to the crux of it. Where are the personal dangers from reopening?

When you think of outbreak clusters, what are the big ones that come to mind? Most people would go to the cruise ships. But you would be wrong. Ship outbreaks don’t even land in the top 50 outbreaks to date.

Ignoring the terrible outbreaks in nursing homes, we find that the biggest outbreaks are in prisons, religious ceremonies, and workplaces, such a meat packing facilities and call centers. Any environment that is enclosed, with poor air circulation and high density of people, spells trouble.

Some of the biggest super-spreading events are:

  • Meat packing: In meat processing plants, densely packed workers must communicate to one another amidst the deafening drum of industrial machinery and a cold-room virus-preserving environment. There are now outbreaks in 115 facilities across 23 states, 5000+ workers infected, with 20 dead. (ref)

  • Weddings, funerals, birthdays: 10% of early spreading events

  • Business networking: Face-to-face business networking like the Biogen Conference in Boston in March.

As we move back to work, or go to a restaurant, let’s look at what can happen in those environments.

Restaurants: Some really great shoe-leather epidemiology demonstrated clearly the effect of a single asymptomatic carrier in a restaurant environment (see below). The infected person (A1) sat at a table and had dinner with 9 friends. Dinner took about 1 to 1.5 hours. During this meal, the asymptomatic carrier released low-levels of virus into the air from their breathing. Airflow (from the restaurant’s various airflow vents) was from right to left. Approximately 50% of the people at the infected person’s table became sick over the next 7 days. 75% of the people on the adjacent downwind table became infected. And even 2 of the 7 people on the upwind table were infected (believed to happen by turbulent airflow). No one at tables E or F became infected, they were out of the main airflow from the air conditioner on the right to the exhaust fan on the left of the room. (Ref)

Workplaces: Another great example is the outbreak in a call center (see below). A single infected employee came to work on the 11th floor of a building. That floor had 216 employees. Over the period of a week, 94 of those people become infected (43.5%: the blue chairs). 92 of those 94 people became sick (only 2 remained asymptomatic). Notice how one side of the office is primarily infected, while there are very few people infected on the other side. While exact number of people infected by respiratory droplets / respiratory exposure versus fomite transmission (door handles, shared water coolers, elevator buttons etc) is unknown. It serves to highlight that being in an enclosed space, sharing the same air for a prolonged period increases your chances of exposure and infection. Another 3 people on other floors of the building were infected, but the authors were not able to trace the infection to the primary cluster on the 11th floor. Interestingly, even though there were considerable interaction between workers on different floors of the building in elevators and the lobby, the outbreak was mostly limited to a single floor (ref). This highlights the importance of exposure and time in the spreading of SARS-CoV2.

Choir: The church choir in Washington State. Even though people were aware of the virus and took steps to minimize transfer; e.g. they avoided the usual handshakes and hugs hello, people also brought their own music to avoid sharing, and socially distanced themselves during practice. A single asymptomatic carrier infected most of the people in attendance. The choir sang for 2 1/2 hours, inside an enclosed church which was roughly the size of a volleyball court.

Singing, to a greater degree than talking, aerosolizes respiratory droplets extraordinarily well. Deep-breathing while singing facilitated those respiratory droplets getting deep into the lungs. Two and half hours of exposure ensured that people were exposed to enough virus over a long enough period of time for infection to take place. Over a period of 4 days, 45 of the 60 choir members developed symptoms, 2 died. The youngest infected was 31, but they averaged 67 years old. (corrected link)

Indoor sports: While this may be uniquely Canadian, a super spreading event occurred during a curling event in Canada. A curling event with 72 attendees became another hotspot for transmission. Curling brings contestants and teammates in close contact in a cool indoor environment, with heavy breathing for an extended period. This tournament resulted in 24 of the 72 people becoming infected. (ref)

Birthday parties / funerals: Just to see how simple infection-chains can be, this is a real story from Chicago. The name is fake. Bob was infected but didn’t know. Bob shared a takeout meal, served from common serving dishes, with 2 family members. The dinner lasted 3 hours. The next day, Bob attended a funeral, hugging family members and others in attendance to express condolences. Within 4 days, both family members who shared the meal are sick. A third family member, who hugged Bob at the funeral became sick. But Bob wasn’t done. Bob attended a birthday party with 9 other people. They hugged and shared food at the 3 hour party. Seven of those people became ill. Over the next few days Bob became sick, he was hospitalized, ventilated, and died.

But Bob’s legacy lived on. Three of the people Bob infected at the birthday went to church, where they sang, passed the tithing dish etc. Members of that church became sick. In all, Bob was directly responsible for infecting 16 people between the ages of 5 and 86. Three of those 16 died.

The spread of the virus within the household and back out into the community through funerals, birthdays, and church gatherings is believed to be responsible for the broader transmission of COVID-19 in Chicago. (ref)

Sobering right?

Commonality of outbreaks

The reason to highlight these different outbreaks is to show you the commonality of outbreaks of COVID-19. All these infection events were indoors, with people closely-spaced, with lots of talking, singing, or yelling. The main sources for infection are home, workplace, public transport, social gatherings, and restaurants. This accounts for 90% of all transmission events. In contrast, outbreaks spread from shopping appear to be responsible for a small percentage of traced infections. (Ref)

Importantly, of the countries performing contact tracing properly, only a single outbreak has been reported from an outdoor environment (less than 0.3% of traced infections). (ref)

So back to the original thought of my post.

Indoor spaces, with limited air exchange or recycled air and lots of people, are concerning from a transmission standpoint. We know that 60 people in a volleyball court-sized room (choir) results in massive infections. Same situation with the restaurant and the call center. Social distancing guidelines don’t hold in indoor spaces where you spend a lot of time, as people on the opposite side of the room were infected.

The principle is viral exposure over an extended period of time. In all these cases, people were exposed to the virus in the air for a prolonged period (hours). Even if they were 50 feet away (choir or call center), even a low dose of the virus in the air reaching them, over a sustained period, was enough to cause infection and in some cases, death.

Social distancing rules are really to protect you with brief exposures or outdoor exposures. In these situations there is not enough time to achieve the infectious viral load when you are standing 6 feet apart or where wind and the infinite outdoor space for viral dilution reduces viral load. The effects of sunlight, heat, and humidity on viral survival, all serve to minimize the risk to everyone when outside.

When assessing the risk of infection (via respiration) at the grocery store or mall, you need to consider the volume of the air space (very large), the number of people (restricted), how long people are spending in the store (workers – all day; customers – an hour). Taken together, for a person shopping: the low density, high air volume of the store, along with the restricted time you spend in the store, means that the opportunity to receive an infectious dose is low. But, for the store worker, the extended time they spend in the store provides a greater opportunity to receive the infectious dose and therefore the job becomes more risky.

Basically, as the work closures are loosened, and we start to venture out more, possibly even resuming in-office activities, you need to look at your environment and make judgments. How many people are here, how much airflow is there around me, and how long will I be in this environment. If you are in an open floorplan office, you really need critically assess the risk (volume, people, and airflow). If you are in a job that requires face-to-face talking or even worse, yelling, you need to assess the risk.

If you are sitting in a well ventilated space, with few people, the risk is low.

If I am outside, and I walk past someone, remember it is “dose and time” needed for infection. You would have to be in their airstream for 5+ minutes for a chance of infection. While joggers may be releasing more virus due to deep breathing, remember the exposure time is also less due to their speed.

While I have focused on respiratory exposure here, please don’t forget surfaces. Those infected respiratory droplets land somewhere. Wash your hands often and stop touching your face!

As we are allowed to move around our communities more freely and be in contact with more people in more places more regularly, the risks to ourselves and our family are significant. Even if you are gung-ho for reopening and resuming business as usual, do your part and wear a mask to reduce what you release into the environment. It will help everyone, including your own business.

This article was inspired by a piece written by Jonathan Kay in Quillete:

COVID-19 Superspreader Events in 28 Countries: Critical Patterns and Lessons

About the author

Erin S. Bromage, Ph.D., is an Associate Professor of Biology at the University of Massachusetts Dartmouth. Dr. Bromage graduated from the School of Veterinary and Biomedical Sciences James Cook University, Australia where his research focused on the epidemiology of, and immunity to, infectious disease in animals. His Post-Doctoral training was at the College of William and Mary, Virginia Institute of Marine Science in the Comparative Immunology Laboratory of late Dr. Stephen Kaattari.

Dr. Bromage’s research focuses on the evolution of the immune system, the immunological mechanisms responsible for protection from infectious disease, and the design and use of vaccines to control infectious disease in animals. He also focuses on designing diagnostic tools to detect biological and chemical threats in the environment in real-time.

Dr. Bromage joined the Faculty of the University of Massachusetts Dartmouth in 2007 where he teaches courses in Immunology and Infectious disease, including a course this semester on the Ecology of Infectious Disease which focused on the emerging SARS-CoV2 outbreak in China.

Good News Monday: It’s Not Easy…

But it’s possible to find a little inspiration.  Also some short distractions.  Hoping these links will work for non-subscribers.

The New York Times also recommends several books to entertain, enlighten and inform.  (The Churchill saga is going on my to-do list.) And I’ll add my own current favorite, a beautifully written novel I finished last week: Ordinary Grace by William Kent Krueger.

THE DAIRY RESTAURANT, by Ben Katchor. (Nextbook/Schocken, $29.95.) The writer and illustrator Ben Katchor has produced a study of, and love song to, Jewish dairy restaurants, which began to flourish in New York City and elsewhere in the late 1800s; a century later, nearly all were defunct. It’s an “obsessive, melancholy and hungry-making” book, our critic Dwight Garner writes. “This is an encyclopedic book, history as told through old newspapers and telephone books and scraps of detail found in letters and memoirs.”

HITLER’S FIRST HUNDRED DAYS: When Germans Embraced the Third Reich, by Peter Fritzsche. (Basic Books, $32.) The historian Peter Fritzsche shows how Hitler and the National Socialists wasted little time after he was appointed chancellor on Jan. 30, 1933, transforming Germany into a place unrecognizable from the republic it had been just a few months before. “There’s something particularly clarifying about the hundred-days framing, especially as it’s presented in this elegant and sobering book, which shows how an unimaginable political transformation can happen astonishingly quickly,” our critic Jennifer Szalai writes.

THE RED LOTUS, by Chris Bohjalian. (Doubleday, $27.95.) In Chris Bohjalian’s new novel, a young man disappears and his girlfriend, an emergency room doctor, falls into a new world of uncertainty and danger when she tries to figure out what happened. “Bohjalian strikes a fine balance between disclosure and secrecy” in deciding what to reveal and when, our reviewer Sarah Lyall writes. And “as suspenseful as it is, ‘The Red Lotus’ is also unexpectedly moving — about friendship, about the connections between people and, most of all, about the love of parents for children and of children for parents.”

BEHELD, by TaraShea Nesbit. (Bloomsbury, $26.) In this plain-spoken and lovingly detailed historical novel, the story of the Mayflower Pilgrims and Plymouth Colony is refracted through the prism of female characters. Despite the book’s quietness of telling, its currency is the human capacity for cruelty and subjugation, of pretty much everyone by pretty much everyone. “At the novel’s core,” Samantha Harvey writes in her review, lies “a critique of Englishness itself. There is a contradiction underpinning the whole project of English imperialism, and Nesbit flags it perfectly. On the one hand, the English pilgrims regard themselves as epitomizing civility, manners and thus superiority. On the other hand, they deploy barbaric cruelty in order to defend that superiority.”

THE EXHIBITION OF PERSEPHONE Q, by Jessi Jezewska Stevens. (Farrar, Straus & Giroux, $26.) This debut novel centers on a young pregnant newlywed in post-9/11 New York City, who unexpectedly finds herself the subject of an ex-boyfriend’s photography exhibit. Implicitly, the book poses the question: How do affections alter appearances? “Stevens’s writing proves that both time and technology are best understood in retrospect, sequences made logical long after each moment has passed,” Haley Mlotek writes in her review. “The novel has a romantic slowness, unfurling gracefully, little by little, to show how quickly the present gives way to the future, or concedes to the past.”

THE SPLENDID AND THE VILE: A Saga of Churchill, Family, and Defiance During the Blitz, by Erik Larson. (Crown, $32.) Larson’s account of Winston Churchill’s leadership during the 12 turbulent months from May 1940 to May 1941, when Britain stood alone and on the brink of defeat, is fresh, fast and deeply moving. “Through the remarkably skillful use of intimate diaries as well as public documents, some newly released, Larson has transformed the well-known record,” Candice Millard writes in her review. “The Blitz — its tense, terror-filled days, the horrors it inflicted — is palpable throughout this book, often by way of the kind of wrenching, carefully chosen facts that not only bring a story to life but also make a reader stop, look up and say to whoever happens to be nearby, ‘Listen to this.’”

LET THE PEOPLE PICK THE PRESIDENT: The Case for Abolishing the Electoral College, by Jesse Wegman. (St. Martin’s, $27.99.) The Electoral College has distorted American politics throughout the country’s history and, as Wegman shows, if it didn’t already exist, no one would think to invent it. “People have been arguing against the Electoral College from the beginning,” Josh Chafetz writes in his review. “But no one, at least in recent years, has laid out the case as comprehensively and as readably as Jesse Wegman does.”

YELLOW BIRD: Oil, Murder, and a Woman’s Search for Justice in Indian Country, by Sierra Crane Murdoch. (Random House, $28.) This painstakingly reported and beautifully written book, Murdoch’s first, examines the effects of fracking on a North Dakota reservation through the eyes of its title subject: a remarkable Native American woman who, determined to solve a murder related to the oil boom, exposes the greed and corruption that fueled it. “Murdoch resists easy portraiture (Indians as pitiful or pathetic or damaged) and blind compassion (Indians as noble sufferers or keepers of special knowledge),” David Treuer writes in his review. “Rather, she finds a way to balance her journalistic curiosity with respect for these complicated people. And Yellow Bird, as a person and as a guide through the mystery surrounding Clarke, is complicated. A fanatic, an addict, sure, but also brilliant, dogged, brave, funny, prickly, radically informed and just as radically nonjudgmental.”

BARRY SONNENFELD, CALL YOUR MOTHER: Memoirs of a Neurotic Filmmaker, by Barry Sonnenfeld. (Hachette, $29.) Sonnenfeld’s moment at the top of Hollywood’s food chain may have been short-lived, but the director of “Men in Black” and “The Addams Family” is an ideal tour guide through the vagaries and hypocrisies of the entertainment industry. “This is also a book about how Sonnenfeld became the artist that he is and the people he blames — namely, his parents — for how he turned out,” Dave Itzkoff writes in his review, noting that the memoir recounts moments of childhood sexual abuse and early work as a cameraman on porn films. But “it’s when Sonnenfeld turns to his career in legitimate cinema that the book really comes alive. As he perceptively observes, the same hang-ups that have inhibited him elsewhere in life are likely what drove him to become a great director of photography.”

THE POWER NOTEBOOKS, by Katie Roiphe. (Free Press, $27.) Best known for her polemical stances on feminist issues, Roiphe here turns her gaze on her romantic relationships, noting moments when she has ceded power to men or even endured their abuse. “Roiphe’s larger goal here is to investigate the lived reality of her romantic dynamics, not to get on a soap box and opine,” Lauren Elkin writes in her review. “The result is a beautifully written and thoughtful book.”

THE DALAI LAMA: An Extraordinary Life, by Alexander Norman. (Houghton Mifflin Harcourt, $30.) A longtime associate of the Dalai Lama provides the most detailed biography to date, exploring the 84-year-old’s life on the world stage and his life inside the world of Tibetan Buddhism. Norman “reveals the Dalai Lama to be a sophisticated thinker and consummate scholar, one whose feet remain firmly on the ground, a trait often obscured by his broken English,” Donald S. Lopez writes in his review. “In keeping with a religion so obsessed with prophecy, the book, written in an engaging prose, ends with an insightful prediction of the legacy of the 14th Dalai Lama, and a cleareyed assessment of the challenges that the 15th will face.”